Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
r-pharm.com

See what CB Insights has to offer

Founded Year

2001

Stage

Debt | Alive

Total Raised

$237M

Last Raised

$237M | 6 yrs ago

About R-Pharm

R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3200 highly qualified specialists, has over 60 branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care.

R-Pharm Headquarter Location

10, Testovskaya st

Moscow, 123317,

Russian Federation

Latest R-Pharm News

AstraZeneca, Sputnik Light Combo Causes Strong Neutralizing Antibody Response, RDIF Says

Sep 27, 2021

AstraZeneca, Sputnik Light Combo Causes Strong Neutralizing Antibody Response, RDIF Says AstraZeneca, Sputnik Light Combo Causes Strong Neutralizing Antibody Response, RDIF Says MOSCOW (Sputnik) - The preliminary results of a clinical study of the combined use of the AstraZeneca and Sputnik Light coronavirus vaccines, carried out by... 27.09.2021, Sputnik International 2021-09-27T15:08+0000 news https://cdnn1.img.sputniknews.com/img/07e5/05/09/1082841555_0:202:3126:1960_1920x0_80_0_0_20d80fec55f6906f485b35f6358f381c.jpg The study began in February 2021 and has since included 100 volunteers.The current data was collected from the first 20 fully vaccinated participants of the trial, who received the AstraZeneca vaccine as the first shot and Sputnik Light, the first component of Russia's Sputnik V based on human adenovirus serotype 26, as the second shot administered 29 days later.The first agreement on joint clinical trials of the combined use of the AstraZeneca and Sputnik Light vaccines was signed by RDIF, Russia's Gamaleya research institute, AstraZeneca and R-Pharm in December 2020. Apart from Azerbaijan, clinical trials of the vaccine combination are underway in the United Arab Emirates and Russia. Belarus has also approved a similar trial to be held there. Sputnik International AstraZeneca, Sputnik Light Combo Causes Strong Neutralizing Antibody Response, RDIF Says © AP Photo / Antonio Calanni Subscribe MOSCOW (Sputnik) - The preliminary results of a clinical study of the combined use of the AstraZeneca and Sputnik Light coronavirus vaccines, carried out by the Russian Direct Investment Fund (RDIF), AstraZeneca and R-Pharm in Azerbaijan, show a strong neutralizing antibody response in the majority of participants, RDIF said on Monday. The study began in February 2021 and has since included 100 volunteers. The current data was collected from the first 20 fully vaccinated participants of the trial, who received the AstraZeneca vaccine as the first shot and Sputnik Light, the first component of Russia's Sputnik V based on human adenovirus serotype 26, as the second shot administered 29 days later. "According to the results of the interim analysis, a fourfold or higher increase in neutralizing antibodies to the spike protein (S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on the 57th day of the study," the Russian fund said in a statement. The first agreement on joint clinical trials of the combined use of the AstraZeneca and Sputnik Light vaccines was signed by RDIF, Russia's Gamaleya research institute, AstraZeneca and R-Pharm in December 2020. Apart from Azerbaijan, clinical trials of the vaccine combination are underway in the United Arab Emirates and Russia. Belarus has also approved a similar trial to be held there.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing R-Pharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

R-Pharm is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R-Pharm Patents

R-Pharm has filed 6 patents.

The 3 most popular patent topics include:

  • Alkylating antineoplastic agents
  • Antineoplastic drugs
  • Cancer treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/12/2016

8/11/2020

Fluoroarenes, Experimental cancer drugs, Protein kinase inhibitors, Piperidines, Cancer treatments

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/12/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/11/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Fluoroarenes, Experimental cancer drugs, Protein kinase inhibitors, Piperidines, Cancer treatments

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

R-Pharm Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

R-Pharm Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.